Stock PDSB PDS BIOTECHNOLOGY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

News PDS Biotechnology Corporation

Equities

PDSB

US70465T1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.98 USD +1.02% Intraday chart for PDS Biotechnology Corporation -3.25% -40.04%
May. 15 PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 10 NetScientific says PDS Biotech's Versamune meets endpoints AN

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PDS Biotechnology: Q1 Earnings Snapshot
AQ
PDS Biotech Provides Business Update and Reports First Quarter 2024 Financial Results
AQ
PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
NetScientific says PDS Biotech's Versamune meets endpoints
AN
PDS Biotechnology Says Head, Neck Cancer Therapy Met Main Goal in Mid-Stage Study
MT
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
AQ
PDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer
CI
PDS Biotech to Participate in Upcoming May 2024 Investor Conferences
AQ
Transcript : PDS Biotechnology Corporation - Special Call
PDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024
AQ
PDS Biotechnology Announces Details of Virtual KOL Event
AQ
PDS Biotechnology Announces Details of Virtual KOL Event
AQ
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
AQ
PDS Biotechnology Corporation Appoints Stephan Toutain as Chief Operating Officer
CI
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune HPV in Combination with KEYTRUDA in Recurrent or Metastatic Head and Neck Cancer
AQ
PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
AQ
B. Riley Securities Adjusts PDS Biotechnology's Price Target to $11 From $14, Maintains Buy Rating
MT
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
AQ
Empire Metals targets key milestones in Australia
AN
Transcript : PDS Biotechnology Corporation, 2023 Earnings Call, Mar 27, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PDSB Stock
  4. News PDS Biotechnology Corporation